Velan (VLN) Q3 2025 earnings summary

Executive summary

• Achieved 18.1% sales growth in Q3 FY25 to $73.4 million, driven by strong execution on a diversified backlog and higher shipments from Italian and Chinese operations.

• Adjusted net income from continuing operations reached $8.5 million, a turnaround from a $7 million loss last year.

• Announced divestiture of all asbestos-related liabilities and exclusive negotiations to sell French subsidiaries for EUR 192.5 million ($198.4 million), both expected to strengthen the balance sheet and reduce risk.

• French subsidiaries reclassified as assets held for sale and discontinued operations.

• Board reinstated a CAD 0.03 per share dividend, payable before February 28, 2025.

Financial highlights

• Q3 sales from continuing operations rose 18.1% year-over-year to $73.4 million; gross profit margin improved to 38.6% from 13.1%.

• Adjusted EBITDA for the quarter was $14.3 million, up from negative $4.1 million last year.

• Nine-month adjusted net income reached $11.9 million, compared to a loss of $14.7 million last year.

• Cash flow from operations after nine months was nearly $20 million, up from a negative $7.6 million a year ago.

• Net loss from continuing operations was $47.8 million, reflecting $74.5 million in restructuring costs, mainly asbestos-related.

Outlook and guidance

• Confident in delivering full-year sales growth and enhanced profitability from continuing operations.

• 83.4% of $298.7 million backlog expected to be delivered in the next 12 months.

• Near-term gross margin expected to be sustainable in the low 30% range.

• Post-transaction, expects balanced capital allocation between reinvestment and shareholder returns.